HRH4 and Pruritus: The discovery of the first selective and potent H4R antagonist JNJ7777120 by Johnson & Johnson Research and Development (now Janssen Pharmaceuticals, Inc.)was essential for evaluating the role of H4R in pathophysiology, including immune reaction-associated pruritus and inflammation (Thurmond et al., 2017).